Source: http://www.google.com/patents/US8052734?dq=6,712,702
Timestamp: 2014-10-01 08:35:22
Document Index: 210512433

Matched Legal Cases: ['Application No. 2005251777', 'Application No. 2', 'Application No. 2', 'Application No. 09009102', 'art 1', 'art 1']

Patent US8052734 - Expandable medical device with beneficial agent delivery mechanism - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign in<nobr>Advanced Patent Search</nobr>PatentsAn expandable issue supporting device of the present invention employs ductile hinges at selected points in the expandable device. When expansion forces are applied to the device as a whole, the ductile hinges concentrate expansion stresses and strains in small well defined areas. The expandable medical...http://www.google.com/patents/US8052734?utm_source=gb-gplus-sharePatent US8052734 - Expandable medical device with beneficial agent delivery mechanismAdvanced Patent SearchPublication numberUS8052734 B2Publication typeGrantApplication numberUS 12/138,721Publication dateNov 8, 2011Filing dateJun 13, 2008Priority dateMar 30, 1998Also published asCA2323358A1, CA2323358C, CA2640588A1, CA2640588C, DE69931403D1, DE69931403T2, DE69931403T3, DE69937879D1, DE69937879T2, DE69938159D1, DE69938159T2, DE69939283D1, EP1071490A1, EP1071490B1, EP2286865A1, EP2286865B1, EP2289593A1, EP2292181A1, US6241762, US6562065, US7279004, US7819912, US7896912, US8052735, US8623068, US20030009214, US20030167085, US20040122505, US20040193249, US20050159806, US20050203609, US20060136038, US20070067026, US20080109071, US20080243070, US20080249609, US20080294242, US20120083873, WO1999049928A1Publication number12138721, 138721, US 8052734 B2, US 8052734B2, US-B2-8052734, US8052734 B2, US8052734B2InventorsJohn F. ShanleyOriginal AssigneeInnovational Holdings, LlcExport CitationBiBTeX, EndNote, RefManPatent Citations (99), Non-Patent Citations (41), Referenced by (1), Classifications (16) External Links: USPTO, USPTO Assignment, EspacenetExpandable medical device with beneficial agent delivery mechanismUS 8052734 B2Abstract An expandable issue supporting device of the present invention employs ductile hinges at selected points in the expandable device. When expansion forces are applied to the device as a whole, the ductile hinges concentrate expansion stresses and strains in small well defined areas. The expandable medical device including ductile hinges provides the advantages of low expansion force requirements, relatively thick walls which are radio-opaque, improved crimping properties, high crush strength, reduced elastic recoil after implantation, and control of strain to a desired level. The expandable tissue supporting device includes a plurality of elongated beams arranged in a cylindrical device and connected together by a plurality of ductile hinges. Although many ductile hinge configurations are possible, the ductile hinges preferably have a substantially constant hinge cross sectional area which is smaller than a beam cross sectional area such that as the device is expanded from a first diameter to a second diameter, the ductile hinges experience plastic deformation while the beams are not plastically deformed.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3657744May 8, 1970Apr 25, 1972Univ MinnesotaMethod for fixing prosthetic implants in a living bodyUS4300244Sep 19, 1979Nov 17, 1981Carbomedics, Inc.Cardiovascular graftsUS4531936Jan 12, 1983Jul 30, 1985Gordon Robert TDevice and method for the selective delivery of drugs to the myocardiumUS4542025Apr 30, 1984Sep 17, 1985The Stolle Research And Development CorporationInjectable, long-acting microparticle formulation for the delivery of anti-inflammatory agentsUS4580568Oct 1, 1984Apr 8, 1986Cook, IncorporatedPercutaneous endovascular stent and method for insertion thereofUS4650466Nov 1, 1985Mar 17, 1987Angiobrade PartnersAngioplasty deviceUS4733665Nov 7, 1985Mar 29, 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graftUS4739762Nov 3, 1986Apr 26, 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graftUS4776337Jun 26, 1986Oct 11, 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graftUS4800882Mar 13, 1987Jan 31, 1989Cook IncorporatedEndovascular stent and delivery systemUS4824436Apr 21, 1987Apr 25, 1989Harvey WolinskyAdministering heparin through catheter with expandable balloonUS4834755Mar 4, 1985May 30, 1989Pfizer Hospital Products Group, Inc.Triaxially-braided fabric prosthesisUS4889119Jan 20, 1988Dec 26, 1989Ethicon, Inc.Surgical fastener made from glycolide-rich polymer blendsUS4916193Aug 1, 1988Apr 10, 1990Allied-Signal Inc.Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactidesUS4955878Dec 8, 1988Sep 11, 1990Biotechnology, Inc.Kit for preventing or treating arterial dysfunction resulting from angioplasty proceduresUS4957508Oct 30, 1987Sep 18, 1990Ube Industries, Ltd.Artificial blood vesselsUS4960790Mar 9, 1989Oct 2, 1990University Of KansasAntitumor agents, water solubleUS4969458Jul 6, 1987Nov 13, 1990Medtronic, Inc.Intracoronary stent and method of simultaneous angioplasty and stent implantUS4989601Sep 22, 1988Feb 5, 1991Medical Engineering & Development Institute, Inc.Method, apparatus, and substance for treating tissue having neoplastic cellsUS4990155May 19, 1989Feb 5, 1991Wilkoff Howard MSurgical stent method and apparatusUS4994071May 22, 1989Feb 19, 1991Cordis CorporationBifurcating stent apparatus and methodUS5017381May 2, 1990May 21, 1991Alza CorporationMulti-unit pulsatile delivery systemUS5019090Sep 1, 1988May 28, 1991Corvita CorporationRadially expandable endoprosthesis and the likeUS5049132Jan 8, 1990Sep 17, 1991Cordis CorporationBalloon catheter for delivering therapeutic agentsUS5053048Nov 8, 1990Oct 1, 1991Cordis CorporationThromboresistant coatingUS5059166Dec 11, 1989Oct 22, 1991Medical Innovative Technologies R & D Limited PartnershipIntra-arterial stent with the capability to inhibit intimal hyperplasiaUS5059178Jan 18, 1991Oct 22, 1991Ya Wang DMethod of percutaneously removing a thrombus from a blood vessel by using catheters and system for removing a thrombus from a blood vessel by using cathetersUS5059211Jun 25, 1987Oct 22, 1991Duke UniversityAbsorbable vascular stentUS5078726Apr 9, 1990Jan 7, 1992Kreamer Jeffry WGraft stent and method of repairing blood vesselsUS5085629Sep 27, 1989Feb 4, 1992Medical Engineering CorporationBiodegradable stentUS5092841May 17, 1990Mar 3, 1992Wayne State UniversityMethod for treating an arterial wall injured during angioplastyUS5102417Mar 28, 1988Apr 7, 1992Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graftUS5139480Aug 22, 1990Aug 18, 1992Biotech Laboratories, Inc.Circumferential strips of thermoplastic material with glass transition temperature below human body temperatureUS5157049Oct 31, 1991Oct 20, 1992The United States Of America As Represented By The Department Of Health & Human ServicesMethod of treating cancers sensitive to treatment with water soluble derivatives of taxolUS5160341Nov 8, 1990Nov 3, 1992Advanced Surgical Intervention, Inc.Resorbable urethral stent and apparatus for its insertionUS5171217Feb 28, 1991Dec 15, 1992Indiana University FoundationMethod for delivery of smooth muscle cell inhibitorsUS5171262Dec 3, 1990Dec 15, 1992Cordis CorporationNon-woven endoprosthesisUS5176617Oct 21, 1991Jan 5, 1993Medical Innovative Technologies R & D Limited PartnershipUse of a stent with the capability to inhibit malignant growth in a vessel such as a biliary ductUS5195984Feb 19, 1991Mar 23, 1993Expandable Grafts PartnershipExpandable intraluminal graftUS5197978Apr 26, 1991Mar 30, 1993Advanced Coronary Technology, Inc.Supports for blood vesselsUS5213580Mar 25, 1992May 25, 1993Endoluminal Therapeutics, Inc.Paving or stabilization a contour interiorUS5223092Apr 30, 1991Jun 29, 1993James River CorporationSheet of paper cover stock material with one textured surface and one smooth surface; book and wall coveringsUS5234456May 7, 1992Aug 10, 1993Pfizer Hospital Products Group, Inc.Hydrophilic stentUS5242399Jun 18, 1992Sep 7, 1993Advanced Cardiovascular Systems, Inc.Method and system for stent deliveryUS5282823Mar 19, 1992Feb 1, 1994Medtronic, Inc.Intravascular radially expandable stentUS5283257Jul 10, 1992Feb 1, 1994The Board Of Trustees Of The Leland Stanford Junior UniversityMycophenolic acidUS5286254Aug 28, 1992Feb 15, 1994Cortrak Medical, Inc.Drug delivery apparatus and methodUS5288711Apr 28, 1992Feb 22, 1994American Home Products CorporationMethod of treating hyperproliferative vascular diseaseUS5290271Jul 29, 1993Mar 1, 1994Jernberg Gary RSurgical implant and method for controlled release of chemotherapeutic agentsUS5292512Dec 20, 1989Mar 8, 1994Centre Internationale De Recherches Dermatologiques (C.I.R.D.)Cosmetic or pharmaceutical composition containing microspheres of polymers or of fatty substances filled with at least one active productUS5304121Nov 22, 1991Apr 19, 1994Boston Scientific CorporationCatheterUS5314688Feb 9, 1993May 24, 1994Eli Lilly And CompanyLocal delivery of dipyridamole for the treatment of proliferative diseasesUS5342348Dec 4, 1992Aug 30, 1994Kaplan Aaron VMethod and device for treating and enlarging body lumensUS5342621Sep 15, 1992Aug 30, 1994Advanced Cardiovascular Systems, Inc.Heparin complexed with lecithin incorporated within biomedical polymer; a stent; mimicking a cell membraneUS5344426Apr 15, 1993Sep 6, 1994Advanced Cardiovascular Systems, Inc.Method and system for stent deliveryUS5380299Aug 30, 1993Jan 10, 1995Med Institute, Inc.Thrombolytic treated intravascular medical deviceUS5383892Nov 6, 1992Jan 24, 1995Meadox FranceStent for transluminal implantationUS5383928Aug 19, 1993Jan 24, 1995Emory UniversityCardiovascular disordersUS5403858Jul 3, 1992Apr 4, 1995Rhone-Poulenc Rorer, S.A.Perfusion solution ethanol free; antitumor agentsUS5407683Oct 1, 1992Apr 18, 1995Research Corporation Technologies, Inc.Pharmaceutical solutions and emulsions containing taxolUS5415869Nov 12, 1993May 16, 1995The Research Foundation Of State University Of New YorkTaxol formulationUS5419760Oct 11, 1994May 30, 1995Pdt Systems, Inc.Medicament dispensing stent for prevention of restenosis of a blood vesselUS5439446Jun 30, 1994Aug 8, 1995Boston Scientific CorporationStent and therapeutic delivery systemUS5439686Feb 22, 1993Aug 8, 1995Vivorx Pharmaceuticals, Inc.Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful thereforUS5441515Apr 23, 1993Aug 15, 1995Advanced Cardiovascular Systems, Inc.Ratcheting stentUS5441745Oct 22, 1984Aug 15, 1995Vestar, Inc.Marking tumors in the body; biodegradableUS5443458Dec 3, 1993Aug 22, 1995Advanced Cardiovascular Systems, Inc.Multilayered biodegradable stent and method of manufactureUS5443496Oct 15, 1993Aug 22, 1995Medtronic, Inc.Intravascular radially expandable stentUS5443497Nov 22, 1993Aug 22, 1995The Johns Hopkins UniversityPercutaneous prosthetic by-pass graft and method of useUS5443500Apr 8, 1994Aug 22, 1995Advanced Cardiovascular Systems, Inc.Intravascular stentUS5447724Nov 15, 1993Sep 5, 1995Harbor Medical Devices, Inc.Has tissue exposed portion to release agent inhibiting adverse reaction to its presence; polymeric surface layer over reservoir; blood oxygenatorUS5449373Mar 17, 1994Sep 12, 1995Medinol Ltd.Articulated stentUS5449382Mar 2, 1994Sep 12, 1995Dayton; Michael P.Minimally invasive bioactivated endoprosthesis for vessel repairUS5449513Aug 11, 1993Sep 12, 1995Research Development Corporation Of JapanPhysical trapping type polymeric micelle drug preparationUS5457113Oct 15, 1993Oct 10, 1995Eli Lilly And CompanyMethods for inhibiting vascular smooth muscle cell proliferation and restinosisUS5460817Mar 12, 1993Oct 24, 1995Allied Colloids Ltd.Particles having anhydrous core comprising solid matrix polymer with active ingredient distributed throughout, outer protective coacervated polymer shellUS5462866Sep 23, 1993Oct 31, 1995Vanderbilt UniversitySemipermeable microspheres encapsulating biological materialUS5464450Mar 21, 1994Nov 7, 1995Scimed Lifesystems Inc.Biodegradable drug delivery vascular stentUS5464650Apr 26, 1993Nov 7, 1995Medtronic, Inc.Intravascular stent and methodUS5472985Sep 2, 1994Dec 5, 1995Neorx CorporationPrevention and treatment of pathologies associated with abnormally proliferative smooth muscle cellsUS5473055Jun 22, 1994Dec 5, 1995Farmitalia Carlo Erba S.R.L.Antitumor agents; better water solubility, side effect reductionUS5496365Jul 15, 1994Mar 5, 1996Sgro; Jean-ClaudeFor supporting walls of an anatomical canalUS5499373Nov 9, 1994Mar 12, 1996Sony CorporationApparatus and methods for designing, analyzing or simulating signal processing functionsUS5500013Jan 13, 1995Mar 19, 1996Scimed Life Systems, Inc.Biodegradable drug delivery vascular stentUS5510077Sep 15, 1994Apr 23, 1996Dinh; Thomas Q.Polymerizing fibrinogen into fibrin in first mold cavity; compressing against surface of second mold cavityUS5512055Sep 30, 1994Apr 30, 1996Leonard BloomBiocompatible, nonbioerodable polymeric coating into which a biologically active agent is adsorbed for sustained releaseUS5516781May 12, 1994May 14, 1996American Home Products CorporationMethod of treating restenosis with rapamycinUS5523092Jan 28, 1994Jun 4, 1996Emory UniversityDevice for local drug delivery and methods for using the sameUS5527344Aug 1, 1994Jun 18, 1996Illinois Institute Of TechnologyFor delivering upon demand a defibrillating drug to a patientUS5534287Nov 29, 1994Jul 9, 1996Schneider (Europe) A.G.Methods for applying an elastic coating layer on stentsUS5545208Dec 21, 1993Aug 13, 1996Medtronic, Inc.Intralumenal drug eluting prosthesisUS5545210Sep 22, 1994Aug 13, 1996Advanced Coronary Technology, Inc.Stent is positioned in martensitic state then transformed into austenitic state; recovers a memorized configuration larger than the mechanically expanded shapeUS5545569May 25, 1995Aug 13, 1996Neorx CorporationImmobilizing capture moiety that binds transforming growth factor-beta, adding serum from patient to form capture complex, adding labeled signal moiety that binds with complex, determining detectable label, presence of factorUS5551954Oct 12, 1994Sep 3, 1996Scimed Life Systems, Inc.Biodegradable drug delivery vascular stentUS5554182Apr 27, 1995Sep 10, 1996Medtronic, Inc.Method for preventing restenosisUS5556413Mar 11, 1994Sep 17, 1996Advanced Cardiovascular Systems, Inc.Coiled stent with locking endsUS5562922Feb 7, 1995Oct 8, 1996Cedars-Sinai Medical CenterDrug incorporating and release polymeric coating for bioprosthesisUS5563146May 26, 1995Oct 8, 1996American Home Products CorporationAdministering rapamycinUS5571089Dec 16, 1994Nov 5, 1996Cardiovascular Dynamics, Inc.Drug delivery catheterNon-Patent CitationsReference1Australian Office Action dated May 3, 2010 corresponding to Application No. 2005251777.2Berk, Bradford C. MD et al., Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty, JACC, vol. 17, No. 6, May 1991: 111B-7B.3Campbell, Gordon R. et al., Phenotypic Modulation of Smooth Muscle Cells in Primary Culture, Vascular Smooth Muscle Cells in Culture, CRC Press 1987, pp. 39-55.4Canadian Search Report dated Mar. 19, 2009 corresponding to Application No. 2,424,305.5Canadian Search Report dated May 27, 2008 corresponding to Application No. 2,424,305.6Clowes, Alexander W. et al., Kinetics of Cellular Proliferation after Arterial Injury, Circulation Research, vol. 58, No. 6, Jun. 1986, pp. 839-845.7Clowes, Alexander W. et al., Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery, Cir Res 56: pp. 139-145, 1985.8Clowes, Alexander W. et al., Suppression by Heparin of smooth muscle cell proliferation in injured arteries, Nature, vol. 265, Feb. 17, 1977, pp. 625-626.9Coburn, Michael D., MD et al., Dose Responsive Suppression of Myointimal Hyperlasia by Dexamethasone, Journal of Vascular Surgery, vol. 15, No. 3, Mar. 1992, pp. 510-518.10Emanuelsson, H. et al., The JOSTENT Coronary Stent Range, JOMED International AB, Helsingborg, Sweden, Chapter 16, p. 123-140.11European Office Action dated Jun. 11, 2010 in Application No. 09009102.6.12Fischman, David L., MD et al., A Randomized Comparison of coronary-Stent Implantation with Balloon Angioplasty in Treatment of Coronary Artery Disease, The New England Journal of Medicine, vol. 331, No. 8, Aug. 25, 1994, 496-501.13Franklin, Stephen, M. MD et al., Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials, Coronary Artery Disease, Mar. 1993, vol. 4, No. 3, 232-242.14Grayson, A.C. Richards et al., "Multi-pulse Drug Delivery From a Resorbable Polymeric Microchip Device", Nature Materials, vol. 2, Nov. 2003, pp. 767-770.15Gregory, Clare R. et al., Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury, Transplantation vol. 55, No. 6, Jun. 1993, pp. 1409-1418.16Guyton , John, R. et al., Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin, Circulation Research, vol. 46, No. 5, May 1980, pp. 625-634.17Hakan, E. et al., The Jostent Coronary Stent Range, Ch. 19.18Halsey, W. (ed.): Dictionary A-K, New ork: Macmillan Educational Co., 1986, p. 491.19Hasson, Goran K., MD., et al., Interferon-Inhibits Arterial Stenosis After Injury, Circulation, vol. 84, No. 3, Sep. 1991, pp. 1266-1272.20Hasson, Goran K., MD., et al., Interferon�Inhibits Arterial Stenosis After Injury, Circulation, vol. 84, No. 3, Sep. 1991, pp. 1266-1272.21Hiatt, B.L. et al., "The Drug-Eluting Stent: Is it the Holy Grail?" Reviews in Cardiovascular medicine, 2001, vol. 2, No. 4, pp. 190-196.22Hwang, C.W. et al., Physiological Transport Forces Govern Drug Distribution for Stent-based Delivery, Circulation, 104, 2001, pp. 600-605.23Jonasson, Lena et al, Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury, Proc. Natl. Acad. Sci USA 85 (1988), pp. 2303-2306.24Kornowski, R. et al., "Slow-Release Taxol coated GR11 Stents Reduce Neointima Formation in a Porcine Coronary in Stent Restenosis Model" Abstract from the American Hear Associatiion's 70th Scientific Sessions, Nov. 9-12, 1997.25Lange, Richard A. MD et al., Restenosis After Coronary Balloon Angioplasty, Annu. Rev. Med. 1991, 42:127-32.26Liu, Ming Wei, MD et al., Restenosis After Coronary Angioplasty Potential Biologic Determinants and Role of Intimal Hyperplasia, Circulation 1989, 79:1374-1387.27Liu, Ming, W. MD et al., Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit, Circulation, vol. 81, No. 3, Mar. 1990, pp. 1089-1093.28Lundergan, Conor F., MD et al., Peptide Inhibition of Myointimal Proliferation by Angiopeptin, a Somatostation Analogue, JACC, vol. 17, No. 6, May 1991: 132B-6B.29Majesky, Mark W., et al., Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery, Circulation Research, vol. 61, No. 2, Aug. 1987, pp. 296-300.30Marx, Steven O. et al., Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells, Circulation Research, 1995; 76(3):412-417.31Nemecek, Georgina M. et al., Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo, The Journal of Pharmacology and Experimental Therapeutics, vol. 248, No. 3, 1998, 1167-1174.32Okada, Tomohisa, MD et al., Localized Release of Perivascular Heparin Inhibits Intimal Proliferaiton after Endothelial Injury without Systemic Anticoagulation, Neurosurgery, vol. 25, No. 6,1989, 892-898.33Poon, Michael et al., Rapamycin Inhibits Vascular Smooth Muscle Cell Migration, J. Clin. Invest., vol. 98, No. 10, Nov. 1996, 2277-2283.34Popma, Jeffrey J. MD et al., Clinical Trials of Restenosis After Coronary Angioplasty, Circulation vol. 84, No. 3, Sep. 1991, pp. 1426-1436.35Powell, Jerry S. et al., Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury, Science, vol. 245, Jul. 14, 1989, pp. 186-188.36Serruys, P. W. et al., Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty-A Multicenter Randomized Double-Blind Placebo-Controlled Trial, Circulation, vol. 88, No. 4, Part 1, Oct. 1993, pp. 1588-1601.37Serruys, P. W. et al., Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty�A Multicenter Randomized Double-Blind Placebo-Controlled Trial, Circulation, vol. 88, No. 4, Part 1, Oct. 1993, pp. 1588-1601.38Serruys, Patrick W. et al., Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries, Circulation, 1996, 93:412-422.39Siekierka, John J., Probing T-Cell Signal Transduction Pathways with the Immunosuppressive Drugs, FK-506 and Rapamycin, Immunologic Research 1994,13:110-116.40Snow, Alan D. et al., Heparin Modulates the Composition of th Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells, American Journal of Pathology, vol. 137, No. 2, Aug. 1990, pp. 313-330.41Vasey, Charles G. et al., Clinical Cardiology: Stress Echo and Coronary Flow, Supplement II Circulation, vol. 80, No. 4, Oct. 1989, II-66.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS20120158125 *Sep 16, 2009Jun 21, 2012Milisav ObradovicStent having expandable elements* Cited by examinerClassifications U.S. Classification623/1.15International ClassificationA61F2/00, A61F2/06, A61F2/82, A61F2/84, A61F2/90Cooperative ClassificationA61F2250/0018, A61F2/915, A61F2250/0068, A61F2002/91541, A61F2/91, A61F2250/0029, A61F2250/0036, A61F2002/91558European ClassificationA61F2/91, A61F2/915RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google